VIII Евразийский конгресс кардиологов. Легочная гипертензия или высший пилотаж кардиологии
VIII Евразийский конгресс кардиологов. Легочная гипертензия или высший пилотаж кардиологии
VIII Евразийский конгресс кардиологов. Обзор симпозиумов. Легочная гипертензия или высший пилотаж кардиологии. Системные гипертензии. 2020; 17 (2): 66–68. DOI:10.26442/2075082X.2020.2.200213
DOI: 10.26442/2075082X.2020.2.200213
________________________________________________
DOI: 10.26442/2075082X.2020.2.200213
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Пандемия COVID-19, нарушив привычное течение жизни, внесла определенные коррективы и в работу научного медицинского сообщества. Благодаря современным технологиям обмен профессиональной информацией не останавливается, он лишь принимает новые формы: конгрессы, конференции, мастер-классы проходят в онлайн-режиме. Предлагаем читателям материалы, подготовленные по докладам, представленным на VIII Евразийском конгрессе кардиологов, прошедшем онлайн 27–28 мая 2020 г.
Список литературы
1. Чазова И.Е. и др. Клинические рекомендации по диагностике и лечению легочной гипертензии. Евразийская ассоциация кардиологов. 2019 г. http://cardio-eur.asia/media/files/clinical_recommendations/Klinicheskiye_rekomendatsii_Yevraziyskoy...
[Chazova I.E. et al. Clinical recommendations for the diagnosis and treatment of pulmonary hypertension. Eurasian Association of Cardiology. 2019 year. http://cardio-eur.asia/media/files/clinical_recommendations/Klinicheskiye_rekomendatsii_Yevraziyskoy... (in Russian).]
2. Чазова И.Е. и др. Легочная гипертензия. Клинические рекомендации. Министерство здравоохранения Российской Федерации. 2016 г. http://www.fesmu.ru/SITE/files/editor/file/fpk_pps/rv29.pdf
[Chazova I.E. et al. Pulmonary hypertension. Clinical recommendations. Ministry of Health of the Russian Federation. 2016 year. http://www.fesmu.ru/SITE/files/editor/file/fpk_pps/rv29.pdf (in Russian).]
3. Черепанова Н.А. и др. Хроническая посттромбоэмболическая легочная гипертензия: новые возможности ведения пациента. Кардиология: Новости. Мнения. Обучение. 2015; 3 (6).
[Cherepanova N.A. et al. Khronicheskaia posttromboembolicheskaia legochnaia gipertenziia: novye vozmozhnosti vedeniia patsienta. Kardiologiia: Novosti. Mneniia. Obuchenie. 2015; 3 (6). (in Russian).]
4. Инструкция по применению лекарственного препарата для медицинского применения Адемпас. Регистрационный номер: ЛП-002639. Данная версия инструкции действует с 05.10.2017.
[Instruktsiia po primeneniiu lekarstvennogo preparata dlia meditsinskogo primeneniia Adempas. Registratsionnyi nomer: LP-002639. Dannaia versiia instruktsii deistvuet s 05.10.2017 (in Russian).]
5. Ghofrani HA et al. Riociguat for the Treatment of Chronic Thromboembolic Pulmonary Hypertension. N Engl J Med 2013; 369: 319–29.
6. Ghofrani HA et al. Riociguat for the Treatment of Pulmonary Arterial Hypertension. N Engl J Med 2013; 369: 330–40. DOI: 10.1056/NEJMoa1209655
7. Evgenov OV et al. NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat Rev Drug Discov 2006; 5 (9): 755–68.
8. Guha M. First-in-class guanylate cyclase stimulator approved for PAH. Nat Biotechnol 2013; 31: 1064. DOI: 10.1038/nbt1213-1064b
9. Lewis J. Rubin et al. Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2). Eur Respir J 2015; 45: 1303–13 DOI: 10.1183/09031936.00090614
10. Gerald Simonneau et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2). Eur Respir J 2015; 45: 1293–1302. DOI: 10.1183/09031936.00087114
11. Hoeper MM et al. RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors. Eur Respir J 2017; 50: 1602425. DOI: 10.1183/13993003.02425-2016
12. Kim NH et al. Chronic thromboembolic pulmonary hypertension. Eur Respir J 2019; 53: 1801915. DOI: 10.1183/13993003.01915-2018
13. Delcroix M et al. Long-Term Outcome of Patients With Chronic Thromboembolic Pulmonary Hypertension: Results From an International Prospective Registry. Circulation 2016; 133: 859–71.
14. Madani M et al. The changing landscape of chronic thromboembolic pulmonary hypertension management. Eur Respir Rev 2017; 26: 170105. DOI: 10.1183/16000617.0105-2017
15. Voorburg JAI et al. Balloon Angioplasty in the Treatment of Pulmonary Hypertension Caused by Pulmonary Embolism. Chest 1988; 94 (Issue 6): 1249–53. DOI: 10.1378/chest.94.6.1249
16. Hiroki Mizoguchi et al. Refined Balloon Pulmonary Angioplasty for Inoperable Patients with Chronic Thromboembolic Pulmonary Hypertension. Circulation: Cardiovascular Interventions. 2012; 5: 748–55. DOI: 10.1161/CIRCINTERVENTIONS.112.971077
17. Xavier Jais et al. Late Breaking Abstract – Balloon pulmonary angioplasty versus riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension: results from the randomised controlled RACE study. Eur Respir J 2019; 54 (Suppl. 63): RCT1885. DOI: 10.1183/13993003.congress-2019.RCT1885
2. Chazova I.E. et al. Pulmonary hypertension. Clinical recommendations. Ministry of Health of the Russian Federation. 2016 year. http://www.fesmu.ru/SITE/files/editor/file/fpk_pps/rv29.pdf (in Russian).
3. Cherepanova N.A. et al. Khronicheskaia posttromboembolicheskaia legochnaia gipertenziia: novye vozmozhnosti vedeniia patsienta. Kardiologiia: Novosti. Mneniia. Obuchenie. 2015; 3 (6). (in Russian).
4. Instruktsiia po primeneniiu lekarstvennogo preparata dlia meditsinskogo primeneniia Adempas. Registratsionnyi nomer: LP-002639. Dannaia versiia instruktsii deistvuet s 05.10.2017 (in Russian).
5. Ghofrani HA et al. Riociguat for the Treatment of Chronic Thromboembolic Pulmonary Hypertension. N Engl J Med 2013; 369: 319–29.
6. Ghofrani HA et al. Riociguat for the Treatment of Pulmonary Arterial Hypertension. N Engl J Med 2013; 369: 330–40. DOI: 10.1056/NEJMoa1209655
7. Evgenov OV et al. NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat Rev Drug Discov 2006; 5 (9): 755–68.
8. Guha M. First-in-class guanylate cyclase stimulator approved for PAH. Nat Biotechnol 2013; 31: 1064. DOI: 10.1038/nbt1213-1064b
9. Lewis J. Rubin et al. Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2). Eur Respir J 2015; 45: 1303–13 DOI: 10.1183/09031936.00090614
10. Gerald Simonneau et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2). Eur Respir J 2015; 45: 1293–1302. DOI: 10.1183/09031936.00087114
11. Hoeper MM et al. RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors. Eur Respir J 2017; 50: 1602425. DOI: 10.1183/13993003.02425-2016
12. Kim NH et al. Chronic thromboembolic pulmonary hypertension. Eur Respir J 2019; 53: 1801915. DOI: 10.1183/13993003.01915-2018
13. Delcroix M et al. Long-Term Outcome of Patients With Chronic Thromboembolic Pulmonary Hypertension: Results From an International Prospective Registry. Circulation 2016; 133: 859–71.
14. Madani M et al. The changing landscape of chronic thromboembolic pulmonary hypertension management. Eur Respir Rev 2017; 26: 170105. DOI: 10.1183/16000617.0105-2017
15. Voorburg JAI et al. Balloon Angioplasty in the Treatment of Pulmonary Hypertension Caused by Pulmonary Embolism. Chest 1988; 94 (Issue 6): 1249–53. DOI: 10.1378/chest.94.6.1249
16. Hiroki Mizoguchi et al. Refined Balloon Pulmonary Angioplasty for Inoperable Patients with Chronic Thromboembolic Pulmonary Hypertension. Circulation: Cardiovascular Interventions. 2012; 5: 748–55. DOI: 10.1161/CIRCINTERVENTIONS.112.971077
17. Xavier Jais et al. Late Breaking Abstract – Balloon pulmonary angioplasty versus riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension: results from the randomised controlled RACE study. Eur Respir J 2019; 54 (Suppl. 63): RCT1885. DOI: 10.1183/13993003.congress-2019.RCT1885
[Chazova I.E. et al. Clinical recommendations for the diagnosis and treatment of pulmonary hypertension. Eurasian Association of Cardiology. 2019 year. http://cardio-eur.asia/media/files/clinical_recommendations/Klinicheskiye_rekomendatsii_Yevraziyskoy... (in Russian).]
2. Чазова И.Е. и др. Легочная гипертензия. Клинические рекомендации. Министерство здравоохранения Российской Федерации. 2016 г. http://www.fesmu.ru/SITE/files/editor/file/fpk_pps/rv29.pdf
[Chazova I.E. et al. Pulmonary hypertension. Clinical recommendations. Ministry of Health of the Russian Federation. 2016 year. http://www.fesmu.ru/SITE/files/editor/file/fpk_pps/rv29.pdf (in Russian).]
3. Черепанова Н.А. и др. Хроническая посттромбоэмболическая легочная гипертензия: новые возможности ведения пациента. Кардиология: Новости. Мнения. Обучение. 2015; 3 (6).
[Cherepanova N.A. et al. Khronicheskaia posttromboembolicheskaia legochnaia gipertenziia: novye vozmozhnosti vedeniia patsienta. Kardiologiia: Novosti. Mneniia. Obuchenie. 2015; 3 (6). (in Russian).]
4. Инструкция по применению лекарственного препарата для медицинского применения Адемпас. Регистрационный номер: ЛП-002639. Данная версия инструкции действует с 05.10.2017.
[Instruktsiia po primeneniiu lekarstvennogo preparata dlia meditsinskogo primeneniia Adempas. Registratsionnyi nomer: LP-002639. Dannaia versiia instruktsii deistvuet s 05.10.2017 (in Russian).]
5. Ghofrani HA et al. Riociguat for the Treatment of Chronic Thromboembolic Pulmonary Hypertension. N Engl J Med 2013; 369: 319–29.
6. Ghofrani HA et al. Riociguat for the Treatment of Pulmonary Arterial Hypertension. N Engl J Med 2013; 369: 330–40. DOI: 10.1056/NEJMoa1209655
7. Evgenov OV et al. NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat Rev Drug Discov 2006; 5 (9): 755–68.
8. Guha M. First-in-class guanylate cyclase stimulator approved for PAH. Nat Biotechnol 2013; 31: 1064. DOI: 10.1038/nbt1213-1064b
9. Lewis J. Rubin et al. Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2). Eur Respir J 2015; 45: 1303–13 DOI: 10.1183/09031936.00090614
10. Gerald Simonneau et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2). Eur Respir J 2015; 45: 1293–1302. DOI: 10.1183/09031936.00087114
11. Hoeper MM et al. RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors. Eur Respir J 2017; 50: 1602425. DOI: 10.1183/13993003.02425-2016
12. Kim NH et al. Chronic thromboembolic pulmonary hypertension. Eur Respir J 2019; 53: 1801915. DOI: 10.1183/13993003.01915-2018
13. Delcroix M et al. Long-Term Outcome of Patients With Chronic Thromboembolic Pulmonary Hypertension: Results From an International Prospective Registry. Circulation 2016; 133: 859–71.
14. Madani M et al. The changing landscape of chronic thromboembolic pulmonary hypertension management. Eur Respir Rev 2017; 26: 170105. DOI: 10.1183/16000617.0105-2017
15. Voorburg JAI et al. Balloon Angioplasty in the Treatment of Pulmonary Hypertension Caused by Pulmonary Embolism. Chest 1988; 94 (Issue 6): 1249–53. DOI: 10.1378/chest.94.6.1249
16. Hiroki Mizoguchi et al. Refined Balloon Pulmonary Angioplasty for Inoperable Patients with Chronic Thromboembolic Pulmonary Hypertension. Circulation: Cardiovascular Interventions. 2012; 5: 748–55. DOI: 10.1161/CIRCINTERVENTIONS.112.971077
17. Xavier Jais et al. Late Breaking Abstract – Balloon pulmonary angioplasty versus riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension: results from the randomised controlled RACE study. Eur Respir J 2019; 54 (Suppl. 63): RCT1885. DOI: 10.1183/13993003.congress-2019.RCT1885
________________________________________________
2. Chazova I.E. et al. Pulmonary hypertension. Clinical recommendations. Ministry of Health of the Russian Federation. 2016 year. http://www.fesmu.ru/SITE/files/editor/file/fpk_pps/rv29.pdf (in Russian).
3. Cherepanova N.A. et al. Khronicheskaia posttromboembolicheskaia legochnaia gipertenziia: novye vozmozhnosti vedeniia patsienta. Kardiologiia: Novosti. Mneniia. Obuchenie. 2015; 3 (6). (in Russian).
4. Instruktsiia po primeneniiu lekarstvennogo preparata dlia meditsinskogo primeneniia Adempas. Registratsionnyi nomer: LP-002639. Dannaia versiia instruktsii deistvuet s 05.10.2017 (in Russian).
5. Ghofrani HA et al. Riociguat for the Treatment of Chronic Thromboembolic Pulmonary Hypertension. N Engl J Med 2013; 369: 319–29.
6. Ghofrani HA et al. Riociguat for the Treatment of Pulmonary Arterial Hypertension. N Engl J Med 2013; 369: 330–40. DOI: 10.1056/NEJMoa1209655
7. Evgenov OV et al. NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat Rev Drug Discov 2006; 5 (9): 755–68.
8. Guha M. First-in-class guanylate cyclase stimulator approved for PAH. Nat Biotechnol 2013; 31: 1064. DOI: 10.1038/nbt1213-1064b
9. Lewis J. Rubin et al. Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2). Eur Respir J 2015; 45: 1303–13 DOI: 10.1183/09031936.00090614
10. Gerald Simonneau et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2). Eur Respir J 2015; 45: 1293–1302. DOI: 10.1183/09031936.00087114
11. Hoeper MM et al. RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors. Eur Respir J 2017; 50: 1602425. DOI: 10.1183/13993003.02425-2016
12. Kim NH et al. Chronic thromboembolic pulmonary hypertension. Eur Respir J 2019; 53: 1801915. DOI: 10.1183/13993003.01915-2018
13. Delcroix M et al. Long-Term Outcome of Patients With Chronic Thromboembolic Pulmonary Hypertension: Results From an International Prospective Registry. Circulation 2016; 133: 859–71.
14. Madani M et al. The changing landscape of chronic thromboembolic pulmonary hypertension management. Eur Respir Rev 2017; 26: 170105. DOI: 10.1183/16000617.0105-2017
15. Voorburg JAI et al. Balloon Angioplasty in the Treatment of Pulmonary Hypertension Caused by Pulmonary Embolism. Chest 1988; 94 (Issue 6): 1249–53. DOI: 10.1378/chest.94.6.1249
16. Hiroki Mizoguchi et al. Refined Balloon Pulmonary Angioplasty for Inoperable Patients with Chronic Thromboembolic Pulmonary Hypertension. Circulation: Cardiovascular Interventions. 2012; 5: 748–55. DOI: 10.1161/CIRCINTERVENTIONS.112.971077
17. Xavier Jais et al. Late Breaking Abstract – Balloon pulmonary angioplasty versus riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension: results from the randomised controlled RACE study. Eur Respir J 2019; 54 (Suppl. 63): RCT1885. DOI: 10.1183/13993003.congress-2019.RCT1885
Авторы
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.